TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $888,860 | -55.4% | 99,425 | +12.3% | 0.00% | -100.0% |
| Q2 2023 | $1,991,378 | 0.0% | 88,545 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,991,378 | +48.9% | 88,545 | +39.3% | 0.00% | 0.0% |
| Q4 2022 | $1,337,045 | -99.9% | 63,578 | +1.8% | 0.00% | 0.0% |
| Q3 2022 | $1,538,177,000 | -4.1% | 62,426 | -5.7% | 0.00% | 0.0% |
| Q2 2022 | $1,603,177,000 | -7.4% | 66,165 | -1.5% | 0.00% | 0.0% |
| Q1 2022 | $1,731,255,000 | -11.7% | 67,181 | +6.3% | 0.00% | 0.0% |
| Q4 2021 | $1,961,355,000 | +56.2% | 63,188 | +22.0% | 0.00% | 0.0% |
| Q3 2021 | $1,255,543,000 | +60.7% | 51,775 | -3.3% | 0.00% | – |
| Q2 2021 | $781,353,000 | -36.6% | 53,554 | +8.4% | 0.00% | -100.0% |
| Q1 2021 | $1,233,143,000 | +17.0% | 49,385 | +27.7% | 0.00% | – |
| Q4 2020 | $1,054,359,000 | – | 38,685 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
| Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
| Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
| MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
| ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
| Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
| Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
| Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |